- CRISPR Therapeutics (CRSP -11.4%), Editas Medicine (EDIT -7.2%) and Intellia Therapeutics (NTLA -6.6%) are all down on the heels of two studies published in Nature Medicine that appear to show the potential for cells edited by CRISPR/Cas9 to seed tumors inside a patient.
- This is not the first time the stocks have sold off in response published research. In January, investors hit sale buttons (before recovering) in response to a study that questioned the viability of the cutting element, the Cas9 enzyme. In December 2017, the stocks sold off on a report that people's unique genetic differences could undermine the efficacy of the gene editing approach.
- Previously: CRISPR/Cas9 gene-editing firms under pressure on paper questioning potential efficacy of cutting element (Jan. 8)
- Previously: CRISPR/Cas9 gene editing players sell off, down as much as 4% (Dec. 12, 2017)
- Now read: The Eleven: Viking Skyrockets, Global Blood Is Fueling
Original article